Hanmi Pharmaceutical's Operating Profit Reaches 60.4 Billion KRW,
Up 4% Year-on-Year
Hanmi Science announced on July 25 that its consolidated operating profit for the second quarter was 34.6 billion KRW, an increase of 30.7% compared to the same period last year. Revenue reached 338.3 billion KRW, up 9.4% year-on-year. Net profit increased by 39.2% to 28.3 billion KRW.
During the same period, Hanmi Pharmaceutical's operating profit was 60.4 billion KRW, a 4% increase compared to the same period last year. However, revenue decreased by 4.5% year-on-year to 361.3 billion KRW. Net profit also declined by 8.6% to 43 billion KRW.
Hanmi Science reported that its healthcare business division's revenue in the second quarter increased by 24.6% year-on-year, reaching 35.1 billion KRW. The pharmaceutical distribution division (Onlinepharm) recorded revenue of 286.5 billion KRW. Hanmi Pharmaceutical's cumulative out-of-hospital prescription performance in the first half of the year surpassed 500 billion KRW.
Beijing Hanmi Pharmaceutical, the local subsidiary in China, posted consolidated revenue of 86.7 billion KRW, operating profit of 16.7 billion KRW, and net profit of 15.5 billion KRW in the second quarter.
Kim Jaekyo, CEO of Hanmi Science, stated, "As a holding company, we will remain faithful to our core role of presenting the future business direction for each affiliate and related company," adding, "We will lead the company to become a holding company with diverse independent revenue streams through direct business operations."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
